RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $570

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $543 to $570.